JNJ-61178104

JNJ-61178104 is a bispecific antibody directed to two inflammatory disease targets and was created under a collaboration between Genmab and Janssen using Genmab's DuoBody technology. JNJ-61178104 is being investigated in a Phase I clinical trial and may potentially be used in treating autoimmune disorders.

Back to top